Inhibitor – Page 7

Alumis Files for IPO to Fund Phase 3 Studies for Second-Generation TYK2 Inhibitor

11 months ago talkbio0Tagged Alumis, immune-mediated diseases, Immunology, Inhibitor, IPO, Phase 3 studies, Precision - temporal, TYK2, TYK2 gene

Alumis, IPO, TYK2 inhibitor, Phase 3 studies, immune-mediated diseases, biotech, precision immunology

BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati

11 months ago talkbio0Tagged Accelerated, Approved, Confirmatory Trial, Inhibitor, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, Pharmacotherapy, Progression-Free Survival, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA

Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data

11 months ago talkbio0Tagged Agammaglobulinaemia tyrosine kinase, Chronic Spontaneous Urticaria, Inhibitor, Long-term, Novartis, Oral cavity, Phase 3 Clinical Trials, remibrutinib

Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor

Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###

11 months ago talkbio0Tagged Autoimmune Diseases, Batoclimab, Biological Factors, FCGRT gene, FcRn, Immunovant, IMVT-1402, Inhibitor, Roivant

Immunovant, IMVT-1402, FcRn inhibitor, Batoclimab, Autoimmune diseases, Vyvgart, Roivant, Biopharmaceuticals

Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer

12 months ago talkbio0Tagged Balversa, Carcinoma, Transitional Cell, Clinical Data, Fibroblast Growth Factor Receptors, Inhibitor, Johnson and Johnson, Malignant neoplasm of urinary bladder

Johnson & Johnson, Balversa, bladder cancer, clinical data, FGFR inhibitor, targeted therapy, urothelial carcinoma.

AbbVie’s Rinvoq Leads Immunology Market as Physicians Rank Players, J&J Sees Decline

1 year ago talkbio0Tagged AbbVie, Approved, Crohn 's disease, Drops - Drug Form, Humira, Immunology, Inhibitor, J&J, Janus kinase, Physicians ' ranking, Players, Rinvoq, United States Food and Drug Administration

AbbVie, Rinvoq, Immunology players, Physicians’ ranking, J&J drop, Humira, Crohn’s disease, FDA approval, JAK inhibitor

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

1 year ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines